Abstract
Tolerance must be maintained to prevent deleterious immune responses. Thus, when tolerance is lost, autoimmunity can result. A number of novel approaches to (re-) induce tolerance for potential clinical applications have been developed in the last decade. Our lab has implemented an immunoglobulin-based gene therapy approach, which may have powerful implications for the treatment of human conditions. These include a variety of autoimmune diseases, transplantation, and the immune response to therapeutic proteins (as in the treatment of hemophilia A) or gene therapy per se. We clone the target (immunogenic) protein in frame with an immunoglobulin heavy chain and deliver it via retrovirus to an activated B cell. In our system, we observe tolerance to multiple epitopes of the protein cloned. An important advantage of this regimen is that identification of the precise peptide epitopes of a target protein is not necessary since selection and presentation by the hosts own antigen presenting cells (APCs) eliminates the issue of HLA polymorphism. Additionally, our data indicate that these tolerogenic B cells are stimulating an endogenous population of regulatory T cells, which are effective at suppressing the immune response in both naïve and primed hosts. Thus, this approach has potential for future clinical therapy.
Keywords: Hemophilia, autoimmunity, regulatory T cells, retroviral gene therapy
Current Gene Therapy
Title: Tolerance Induction by Gene Transfer to Lymphocytes
Volume: 7 Issue: 5
Author(s): Jonathan Skupsky, Yan Su, Tie-Chi Lei and David W. Scott
Affiliation:
Keywords: Hemophilia, autoimmunity, regulatory T cells, retroviral gene therapy
Abstract: Tolerance must be maintained to prevent deleterious immune responses. Thus, when tolerance is lost, autoimmunity can result. A number of novel approaches to (re-) induce tolerance for potential clinical applications have been developed in the last decade. Our lab has implemented an immunoglobulin-based gene therapy approach, which may have powerful implications for the treatment of human conditions. These include a variety of autoimmune diseases, transplantation, and the immune response to therapeutic proteins (as in the treatment of hemophilia A) or gene therapy per se. We clone the target (immunogenic) protein in frame with an immunoglobulin heavy chain and deliver it via retrovirus to an activated B cell. In our system, we observe tolerance to multiple epitopes of the protein cloned. An important advantage of this regimen is that identification of the precise peptide epitopes of a target protein is not necessary since selection and presentation by the hosts own antigen presenting cells (APCs) eliminates the issue of HLA polymorphism. Additionally, our data indicate that these tolerogenic B cells are stimulating an endogenous population of regulatory T cells, which are effective at suppressing the immune response in both naïve and primed hosts. Thus, this approach has potential for future clinical therapy.
Export Options
About this article
Cite this article as:
Skupsky Jonathan, Su Yan, Lei Tie-Chi and Scott W. David, Tolerance Induction by Gene Transfer to Lymphocytes, Current Gene Therapy 2007; 7 (5) . https://dx.doi.org/10.2174/156652307782151443
DOI https://dx.doi.org/10.2174/156652307782151443 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, further converted to melatonin by ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunomodulation in Multiple Sclerosis by Phytotherapy
Current Immunology Reviews (Discontinued) Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Oligodendrocytes in the Molecular Pathobiology and Potential Molecular Treatment of Cervical Spondylotic Myelopathy
Current Medicinal Chemistry The Pathophysiology of Heme in the Brain
Current Alzheimer Research New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) The Influence of Erythropoietin and Proinflammatory Cytokines in the Development of Cerebral Palsy
Vascular Disease Prevention (Discontinued) Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design The Development of the Combination Drug Leukovir<sup>®</sup> Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Current Drug Targets Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Update to Medicinal Chemistry of Nicotinamide in the Treatment of Ischemia and Reperfusion
Medicinal Chemistry Reviews - Online (Discontinued) Role of Caspases in Activation-Induced Cell Death of Neuroglia
Current Enzyme Inhibition